NCT06437496View on ClinicalTrials.gov

68Ga-AAZTA-093 PET/CT: First-in-human Study

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

July 1, 2024

Study Completion Date

October 1, 2024

Conditions
Malignant Neoplasm of Prostate
Interventions
DRUG

68Ga-AAZTA-093

Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-AAZTA-093. Tracer doses of 68Ga-AAZTA-093 will be used to image lesions of prostate cancer by PET/CT.

DRUG

68Ga-PSMA-11//68Ga-PSMA-617

Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-PSMA-11//68Ga-PSMA-617. Tracer doses of 68Ga-PSMA-11/68Ga-PSMA-617 will be used to image lesions of prostate cancer by PET/CT.

Trial Locations (1)

350005

RECRUITING

Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

First Affiliated Hospital of Fujian Medical University

OTHER